It was first approved for the treatment of patients with unresectable or metastatic HER2-positive breast cancer by the Food and Drug Administration (FDA) in the US (December 2019) [14], followed by approval in Japan (March 2020) for the same indication. The gene discussed is ERBB2; the disease is breast cancer.